重组人腺病毒p53提高肺腺癌放射敏感性的实验观察

Radiosensitivity enhanced by recombinant adenovirus p53 in lung adenocarcinoma

目的:评价重组人腺病毒p53(rAd-p53)注射液对肺腺癌A2细胞系放射敏感性的影响。方法:实验分空白对照组(C组)、照射组(R组)、加药组(D组)、照射加药组(R+D组),利用单击多靶数学模型拟合辐射剂量效应曲线,应用细胞克隆形成实验观察各组细胞存活情况,应用流式细胞仪技术分析各组细胞周期分布和细胞凋亡率。结果:R组与R+D组平均致死剂量(D0)分别为1.26Gy、0.45Gy,准阈剂量(Dq)分别为3.37Gy、1.05Gy;两组放射增敏比SERD(0D0之比)为2.8,SERD(qDq之比)为3.21;流式细胞仪结果提示R+D组G2/M期细胞比例及细胞凋亡率增加最明显(P<0.05),二者之间存在正相关关系(rs=0.989,P<0.05)。结论:rAd-p53对体外培养的肺腺癌A2细胞具有放射增敏作用。

Objective： To evaluate the effect of recombinant adenovirus p53 injection （rAd-p53） on the radiosensitivity of human lung adenocarcinoma cell line A2. Methods： A2 cells were divided into control group （group C）,drug treatment group （group D）,radiation therapy group （group R）,and radiation therapy plus drug treatment group （group R＋D）. Radiation dose-effect curve was obtained by using single-hit,multi-target model. The cell survival was detected by cloning assay,and the cell cycle and cell apoptosis rate were determined by using flow cytometry. Results： The D0 and Dq values were 1.26 and 3.37 Gy in group R and 0.45 and 1.05 Gy in group R＋D. The SERD0 and SERDq were 2.8 and 3.21,respectively. The results of flow cytometry indicated that rAd-p53 induced G2/M-phase arrest and increased cell apoptosis rate significantly （P 〈 0.05）. The percentage of cells in G2/M phase positively correlated with the cell apoptosis rate （rs=0.989,P 〈 0.05）. Conclusion： rAd-p53 is a potential radiosensitizer for lung adenocarcinoma cell line A2 in vitro.